Partnering in CardioMetabolic Diseases
Our growing portfolio of partnerships in CardioMetabolic diseases spans the discovery and development value chain and includes partnerships with academia and industry including our long-standing global strategic alliance with Eli Lilly and Company established in 2011. We are actively pursuing new early-science collaborations in our areas of partnering interest and look forward to expanding our community of innovation partners in CardioMetabolic diseases.
Our experience
Our portfolio of marketed products for CardioMetabolic diseases includes treatments for:
- Thromboembolic diseases
- Type 2 diabetes
- Acute myocardial infarction
- Hypertension
- Cardio-renal risk-reduction.
We have extensive experience in large-scale clinical trials in CardioMetabolic diseases, and are currently investigating our compounds in more than 20 studies involving over 60,000 patients.
Our research and development centers for CardioMetabolic diseases are located in Germany and the USA, where our scientists are working with many academic and industry partners to discover and develop breakthrough treatments that continue our tradition of innovation excellence in CardioMetabolic disease research.
Our CardioMetabolic disease research focus
- Type 2 diabetes
- Micro and macrovascular complications of type 2 diabetes, with a focus on chronic kidney diseases and diabetic nephropathy as well as diabetic retinopathy
- Non-alcoholic steatohepatitis (NASH) and liver fibrosis
- Obesity.
Our partnering interests in CardioMetabolic disease
Our specific partnering interests offer various opportunities for collaboration with a focus on therapies that address microvascular and macrovascular complications of diabetes and the metabolic syndrome:
- Liver diseases: Non-alcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis
- Diabetic retinopathy (DME, PDR, nPDR)
- Chronic kidney disease: Chronic kidney disease, and approaches targeting pathophysiologies in the cardio-renal axis, including heart failure, acute kidney injury, renal inflammation and fibrosis
- Novel obesity treatments achieving weight loss > 10%
- Breakthrough treatments for type 2 diabetes, Pancreas recovery options.
For more information about CardioMetabolic partnering opportunities please contact:
Dr. Johannes Zanzinger
Phone: +49 7351 54 4271
Email: johannes.zanzinger@boehringer-ingelheim.com
Dr. Monica Cheng
Phone: +1 203 798 5268
Email: monica.cheng@boehringer-ingelheim.com
Dr. Manuel Baader
Phone: +49 7351 54 96665
Email: manuel.baader@boehringer-ingelheim.com
-
DOWNLOAD PDF (139.18 KB)
CardioMetabolic Partnering Interests